Novartis Announces Overall Survival Data for Kisqali in Advanced Breast Cancer

Novartis today announced overall survival (OS) data from the Phase 3 MONALEESA-2 trial showing that Kisqali (ribociclib) plus letrozole significantly improves OS in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. The median OS was 63.9 months for Kisqali plus letrozole versus 51.4 months for placebo plus letrozole. The hazard ratio for OS was 0.76, representing a 24% reduction in the risk of death. These results establish Kisqali plus letrozole as a standard of care in the first-line treatment of HR+ HER2- advanced breast cancer.